Results from the CHOICE-2 trial show a 15% absolute increase in excellent functional outcomes with intra-arterial alteplase ...
With the study adding to a mix of conflicting trial results, it’s not yet time to update guidelines, Shyam Prabhakaran says.
MedPage Today on MSN
Stroke trial tips scale further to favor intra-arterial lytic after EVT
CHOICE-2 supports intra-arterial alteplase after successful reperfusion ...
The 5-second intravenous bolus offers faster, simpler administration than Activase. (HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results